Facebook
X
LinkedIn
Forward
Jeni Herrera-Mullar, MGC, LCGC, DMA, is a Principal Clinical Scientist at Ambry Genetics. As a member of the Gene Team, Jeni specializes in gene-disease relationship assessment and gene characterization, with a focus on hereditary cancer predisposition genes. She has contributed to the development of Ambry frameworks for gene-disease validity and has been involved in publications elucidating the phenotype in novel and established hereditary cancer genes. Jeni is an active participant in multiple professional working groups, including the ClinGen Hereditary Cancer GCEP and Hereditary Gastric Cancer VCEP, and the International Gastric Cancer Linkage Consortium, and she regularly presents at conferences on the importance of gene characterization in diagnostics and patient care.
Presenter: Nida Karra, PhD
Variant Assessment Scientist II at Ambry Genetics
Nida Karra earned her PhD in Genetics and Developmental Biology from UT Southwestern, where she investigated the molecular mechanisms of mouse eye development. Her postdoc was more focused in human disease where she worked on identifying the genetic causes of rare congenital urogenital anomalies in children. She has over five years of industry experience in variant classification and have been at Ambry for more than two. She has a passion for copy number variants and complex genomic structural rearrangements.
Presenter: Emily Kudalkar, PhD, FACMG
Associate Laboratory Director at Ambry Genetics
Dr. Emily Kudalkar, PhD, FACMG, is a board-certified cytogenetic and molecular geneticist currently serving as an Associate Laboratory Director at Ambry Genetics. With a focus on advancing diagnostic capabilities, her current work is centered on identifying and classifying copy number and structural variants through the application of microarray and whole genome sequencing. Her extensive expertise spans diverse areas of clinical genetics, including cytogenetics (cancer and congenital disorders), somatic molecular tumor testing, pharmacogenomics, and rare disease. Dr. Kudalkar's professional experience includes leadership roles in both academic and industrial laboratories. She earned her PhD in Molecular & Cellular Biology from Northwestern University, followed by postdoctoral research at both the University of Washington and the Lab for Molecular Medicine at Harvard University, culminating in the completion of a Laboratory Genetics and Genomics Fellowship at the University of Colorado Anschutz Medical School.
Presenter: Colin Young, PhD
Senior Variant Assessment Scientist at Ambry Genetics
Colin Young received his PhD from the University of Utah in 2018. He joined the oncology variant assessment team at Ambry in 2019, where he is a gene expert on about 20 hereditary cancer predisposition genes. In his role at Ambry, Colin has extensive experience in NGS panel testing, RNA analysis, Del/Dup analysis, exome analysis, and incorporating long-read sequencing data for use in variant interpretation.
Presenter: Tim Moss, MD/PhD, FACMG
Senior Variant Assessment Scientist at Ambry Genetics
Dr. Tim Moss is a Clinical and Molecular Geneticist with 15 years clinical experience in rare hereditary and metabolic disease.
Moderator: Holly LaDuca, MS, CGC
Clinical Strategy Manager at Ambry Genetics
Holly LaDuca is a Clinical Strategy Manager at Ambry Genetics, focusing on hereditary cancer. After beginning her career as a community-based cancer genetic counselor, she has spent over 10 years applying her genetic counseling skillset in laboratory and digital health settings. During this time, she has collaborated on 60+ publications. Ms. LaDuca is concurrently pursuing a PhD in Translational Health Science to help bridge gaps between research and practice and to integrate implementation science principles into clinical genetics and precision public health. She also enjoys engaging with genetic counseling students, especially to support thesis projects.
Educational Independence and Disclosure Policy
EducateNext is committed to providing independent, objective, and evidence-based educational content. None of the individuals in control of this content—including our planners, reviewers, and approval faculty—have any financial relationships with ineligible companies to disclose. For all educational sessions, speaker-specific disclosures regarding any potential conflicts of interest are required and will always be shared directly with learners at the beginning of their respective presentations.